FOUND: 2 | Mind Blowing Facts

Hello, Haleon: GlaxoSmithKline reveals name of £60bn consumer health spin-out

THE new consumer healthcare company to be spun out from GlaxoSmithKline will be named Haleon,  it was announced today.

Evening Standard · Feb 22, 2022

Screeching U-turn as Unilever’s shareholders balk at £50bn GSK deal

Riot in ranks sends ‘strong message’ against tilt at GlaxoSmithKline’s consumer division

The Guardian - UK · Feb 10, 2022

Unilever CEO Alan Jope serves up ‘red meat’ with buyback and pledge not to do big deals

Under-pressure Unilever CEO Alan Jope today tried to placate restless investors with “red meat” offerings as he tries to move on from a botched bid for GlaxoSmithKline’s consumer healthcare business.

Evening Standard · Feb 10, 2022

Marmite and Dove maker Unilever to cut 1,500 jobs in huge global restructuring

Unilever products include Domestos bleach, Ben & Jerry's ice cream and Hellman’s mayonnaise. The announcement comes after it lost a takeover bid for GlaxoSmithKline - the maker of Aquafresh toothpaste and Panadol

Daily Mirror · Jan 25, 2022

Unilever’s doomed £50bn GlaxoSmithKline bid was a ‘near-death experience’

Fund manager Terry Smith made a fresh attack on Unilever following the collapse of its bid for GlaxoSmithKline’s consumer-health unit, saying the Dove soap maker needs to focus more on fixing its own business.

Evening Standard · Jan 20, 2022

Unilever won't up £50bn offer for GSK-Pfizer unit

LONDON: Consumer goods giant Unilever on Wednesday said it would not increase a £50-billion offer for the consumer healthcare unit owned by pharmaceutical groups GlaxoSmithKline and Pfizer.

Bangkok Post · Jan 20, 2022

Unilever won't top $68B bid for GSK consumer healthcare unit

Unilever, the maker of Vaseline skin care products and Dove soap, says it won’t increase a 50 billion-pound ($68.2 billion) offer for GlaxoSmithKline’s consumer healthcare unit that was rejected last week

The Independent UK · Jan 19, 2022

Unilever vows not to increase GSK bid

Unilever has effectively ruled out a fourth takeover approach for GlaxoSmithKline’s consumer healthcare business after vowing not to increase its offer.

Evening Standard · Jan 19, 2022

Unilever punished by City for failed £50bn tilt at GSK

A PROPOSED fire-sale of under-performing food assets failed to stem the blood-letting at Unilever today as the City issued a damning verdict over its failed £50 billion tilt at GlaxoSmithKline.

Evening Standard · Jan 17, 2022